# Tovecimig

Source: https://onco.cc/drugs/tovecimig/  
OnCo record `tovecimig` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tovecimig is an experimental bispecific antibody from Compass Therapeutics in phase 3 trials for biliary tract cancer and bladder & urothelial cancer, aimed at VEGF / VEGFR.

## Summary

Tovecimig (CTX-009) is a bispecific antibody developed by Compass Therapeutics. Its target is VEGF / VEGFR (the sponsor names DLL4 x VEGF-A). The sponsor states: Simultaneously targets Delta-like ligand 4 (DLL4) and VEGF-A to inhibit tumour angiogenesis. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05506943 (A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)), in biliary tract cancer and bladder & urothelial cancer. The largest, NCT05506943, plans to enrol 168 participants (actual) with primary completion expected 2027-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: CTX-009
- Modality: bispecific antibody
- Mechanism: Simultaneously targets Delta-like ligand 4 (DLL4) and VEGF-A to inhibit tumour angiogenesis.

## Sources

- ClinicalTrials.gov: trials of Tovecimig: https://clinicaltrials.gov/search?intr=Tovecimig
- Sponsor pipeline page: https://www.compasstherapeutics.com/pipeline

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- targets: [DLL4](https://onco.cc/targets/dll4/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Compass Therapeutics](https://onco.cc/companies/compass-therapeutics/)
- trials: [A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)](https://onco.cc/trials/companion-002/), [Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer](https://onco.cc/trials/nct07662031/)

---
JSON: https://onco.cc/api/v1/entities/tovecimig.json